Looking beyond the hype: Applied AI and machine learning in translational medicine

EBioMedicine

Volumn 47, Issue , 2019, Pages 607-615

  Toh, Tzen S ^a   Dondelinger, Frank ^b   Wang, Dennis ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b LANCASTER UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Artificial intelligence; Drug discovery; Genomic medicine; Imaging; Machine learning; Translational medicine

Indexed keywords

CHEMICAL COMPOUND;

ARTIFICIAL INTELLIGENCE; CELL STRUCTURE; CHEMICAL STRUCTURE; COST EFFECTIVENESS ANALYSIS; DEEP LEARNING; DEEP NEURAL NETWORK; DRUG DESIGN; DRUG REPOSITIONING; DRUG SCREENING; FEEDBACK SYSTEM; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; MACHINE LEARNING; MEDICINE; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE PROPERTY RELATION; RECURRENT NEURAL NETWORK; REPRODUCIBILITY; REVIEW; ANIMAL; DRUG DEVELOPMENT; GENOMICS; MOLECULAR IMAGING; PERSONALIZED MEDICINE; PROCEDURES; TRANSLATIONAL RESEARCH;

ANIMALS; ARTIFICIAL INTELLIGENCE; DRUG DISCOVERY; GENOMICS; HUMANS; MACHINE LEARNING; MOLECULAR IMAGING; PRECISION MEDICINE; REPRODUCIBILITY OF RESULTS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 85071139508     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2019.08.027     Document Type: Review

References (70)

1. Esteva A, Robicquet A, Ramsundar B, Kuleshov V, DePristo M, Chou K, et al. A guide to deep learning in healthcare. Nat Med 2019;25:24–9.
2. Watson DS, Krutzinna J, Bruce IN, Griffiths CE, McInnes IB, Barnes MR, et al. Clinical applications of machine learning algorithms: beyond the black box. BMJ 2019;364:l886.
3. He J, Baxter SL, Xu J, Xu J, Zhou X, Zhang K. The practical implementation of artificial intelligence technologies in medicine. Nat Med 2019;25:30–6.
4. Artificial Intelligence and Machine Learning in Software as a Medical Device. US Food and Drug Administration n.d. https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-software-medical-device#whatis (accessed July 19, 2023).
5. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics 2016;47:20–33. doi:10.1016/j.jhealeco.2016.01.012.
6. Merk D, Grisoni F, Friedrich L, Schneider G. Tuning artificial intelligence on the de novo design of natural-product-inspired retinoid X receptor modulators. Communications Chemistry 2018;1. doi:10.1038/s42004-018-0068-1.
7. Gupta A, Müller AT, Huisman BJH, Fuchs JA, Schneider P, Schneider G. Generative Recurrent Networks for De Novo Drug Design. Molecular Informatics 2018;37:1700111. doi:10.1002/minf.201700111.
8. Popova M, Isayev O, Tropsha A. Deep reinforcement learning for de novo drug design. Science Advances 2018;4:eaap7885. doi:10.1126/sciadv.aap7885.
9. Segler MHS, Preuss M, Waller MP. Planning chemical syntheses with deep neural networks and symbolic AI. Nature 2018;555:604–10.
10. Olivecrona M, Blaschke T, Engkvist O, Chen H. Molecular de-novo design through deep reinforcement learning. J Cheminform 2017;9:48.
11. Shameer K, Johnson K, Glicksberg BS, Hodos R, Readhead B, Tomlinson MS, et al. Prioritizing Small Molecule as Candidates for Drug Repositioning using Machine Learning n.d. doi:10.1101/331975.
12. Kogej T, Blomberg N, Greasley PJ, Mundt S, Vainio MJ, Schamberger J, et al. Big pharma screening collections: more of the same or unique libraries? The AstraZeneca–Bayer Pharma AG case. Drug Discovery Today 2013;18:1014–24. doi:10.1016/j.drudis.2012.10.011.
13. Engels MFM, Gibbs AC, Jaeger EP, Verbinnen D, Lobanov VS, Agrafiotis DK. A cluster-based strategy for assessing the overlap between large chemical libraries and its application to a recent acquisition. J Chem Inf Model 2006;46:2651–60.
14. Schamberger J, Grimm M, Steinmeyer A, Hillisch A. Rendezvous in chemical space? Comparing the small molecule compound libraries of Bayer and Schering. Drug Discov Today 2011;16:636–41.
15. Di Veroli GY, Fornari C, Wang D, Mollard S, Bramhall JL, Richards FM, et al. Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics 2016;32:2866–8.
16. Napolitano F, Zhao Y, Moreira VM, Tagliaferri R, Kere J, D'’Amato M, et al. Drug repositioning: a machine-learning approach through data integration. J Cheminform 2013;5:30.
17. Shameer K, Glicksberg BS, Hodos R, Johnson KW, Badgeley MA, Readhead B, et al. Systematic analyses of drugs and disease indications in RepurposeDB reveal pharmacological, biological and epidemiological factors influencing drug repositioning. Briefings in Bioinformatics 2018;19:656–78. doi:10.1093/bib/bbw136.
18. Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y, et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res 2014;42:D1091–7.
19. Costello JC, Heiser LM, Georgii E, Gönen M, Menden MP, Wang NJ, et al. A community effort to assess and improve drug sensitivity prediction algorithms. Nat Biotechnol 2014;32:1202–12.
20. Menden MP, Wang D, Mason MJ, Szalai B, Bulusu KC, Guan Y, et al. Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen. Nat Commun 2019;10:2674.
21. Yu K-H, Zhang C, Berry GJ, Altman RB, Ré C, Rubin DL, et al. Predicting non-small cell lung cancer prognosis by fully automated microscopic pathology image features. Nat Commun 2016;7:12474.
22. Coudray N, Ocampo PS, Sakellaropoulos T, Narula N, Snuderl M, Fenyö D, et al. Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning. Nature Medicine 2018;24:1559–67. doi:10.1038/s41591-018-0177-5.
23. Ozaki Y, Yamada H, Kikuchi H, Hirotsu A, Murakami T, Matsumoto T, et al. Label-free classification of cells based on supervised machine learning of subcellular structures. PLoS One 2019;14:e0211347.
24. Doan M, Carpenter AE. Leveraging machine vision in cell-based diagnostics to do more with less. Nature Materials 2019;18:414–8. doi:10.1038/s41563-019-0339-y.
25. Simm J, Klambauer G, Arany A, Steijaert M, Wegner JK, Gustin E, et al. Repurposing High-Throughput Image Assays Enables Biological Activity Prediction for Drug Discovery. Cell Chem Biol 2018;25:611–8.e3.
26. Hofmarcher M, Rumetshofer E, Clevert D-A, Hochreiter S, Klambauer G. Accurate Prediction of Biological Assays with High-Throughput Microscopy Images and Convolutional Networks. J Chem Inf Model 2019;59:1163–71.
27. Nassar M, Doan M, Filby A, Wolkenhauer O, Fogg DK, Piasecka J, et al. Label-Free Identification of White Blood Cells Using Machine Learning. Cytometry Part A 2019. doi:10.1002/cyto.a.23794.
28. Nagpal K, Foote D, Liu Y, Chen P-HC, Wulczyn E, Tan F, et al. Development and validation of a deep learning algorithm for improving Gleason scoring of prostate cancer. NPJ Digit Med 2019;2:48.
29. Steele KE, Tan TH, Korn R, Dacosta K, Brown C, Kuziora M, et al. Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis. J Immunother Cancer 2018;6:20.
30. Seashore-Ludlow B, Rees MG, Cheah JH, Cokol M, Price EV, Coletti ME, et al. Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. Cancer Discov 2015;5:1210–23.
31. The Cancer Genome Atlas. National Cancer Institute 2018. https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga (accessed June 24, 2019).
32. Dugger SA, Platt A, Goldstein DB. Drug development in the era of precision medicine. Nat Rev Drug Discov 2017;17:183.
33. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603–7.
34. Mamatjan Y, Agnihotri S, Goldenberg A, Tonge P, Mansouri S, Zadeh G, et al. Molecular Signatures for Tumor Classification: An Analysis of The Cancer Genome Atlas Data. J Mol Diagn 2017;19:881–91.
35. Rajkomar A, Oren E, Chen K, Dai AM, Hajaj N, Hardt M, et al. Scalable and accurate deep learning with electronic health records. Npj Digital Medicine 2018;1:18.
36. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med 2010;363:1290–1290.
37. Catalanotti F, Solit DB, Pulitzer MP, Berger MF, Scott SN, Iyriboz T, et al. Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. Clin Cancer Res 2013;19:2257–64.
38. Infinium HumanMethylation450K BeadChip Documentation n.d. http://emea.support.illumina.com/array/array_kits/infinium_humanmethylation450_beadchip_kit/documentation.html (accessed July 29, 2019).
39. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012;483:570–5.
40. Ghandi M, Huang FW, Jané-Valbuena J, Kryukov GV, Lo CC, McDonald ER 3rd, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 2019;569:503–8.
41. Behan FM, Iorio F, Picco G, Gonçalves E, Beaver CM, Migliardi G, et al. Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens. Nature 2019;568:511–6. doi:10.1038/s41586-019-1103-9.
42. Yu C, Mannan AM, Yvone GM, Ross KN, Zhang Y-L, Marton MA, et al. High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. Nat Biotechnol 2016;34:419–23.
43. Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B, et al. Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell 2017;31:737–54.e6.
44. Shen R, Olshen AB, Ladanyi M. Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. Bioinformatics 2009;25:2906–12.
45. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61–70.
46. Cabassi A, Kirk PDW. Multiple kernel learning for integrative consensus clustering of genomic datasets 2019.
47. Ma T, Zhang A. Affinity network fusion and semi-supervised learning for cancer patient clustering. Methods 2018;145:16–24.
48. Gabasova E, Reid J, Wernisch L. Clusternomics: Integrative context-dependent clustering for heterogeneous datasets. PLoS Comput Biol 2017;13:e1005781.
49. Lock EF, Dunson DB. Bayesian consensus clustering. Bioinformatics 2013;29:2610–6.
50. Kirk P, Griffin JE, Savage RS, Ghahramani Z, Wild DL. Bayesian correlated clustering to integrate multiple datasets. Bioinformatics 2012;28:3290–7.
51. Wang B, Mezlini AM, Demir F, Fiume M, Tu Z, Brudno M, et al. Similarity network fusion for aggregating data types on a genomic scale. Nat Methods 2014;11:333–7.
52. Li J, Pan C, Zhang S, Spin JM, Deng A, Leung LLK, et al. Decoding the Genomics of Abdominal Aortic Aneurysm. Cell 2018;174:1361–72.e10. doi:10.1016/j.cell.2018.07.021.
53. Normand R, Du W, Briller M, Gaujoux R, Starosvetsky E, Ziv-Kenet A, et al. Found In Translation: a machine learning model for mouse-to-human inference. Nat Methods 2018;15:1067–73.
54. Mourragui S, Loog M, Reinders MJT, Wessels LFA. PRECISE: A domain adaptation approach to transfer predictors of drug response from pre-clinical models to tumors n.d. doi:10.1101/536797.
55. Buil-Bruna N, López-Picazo J-M, Martín-Algarra S, Trocóniz IF. Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications. Oncologist 2016;21:220–32.
56. Aziz HA, Alshekhabobakr HM. Health Informatics Tools to Improve Utilization of Laboratory Tests. Lab Med 2017;48:e30–5.
57. Vayena E, Blasimme A, Cohen IG. Machine learning in medicine: Addressing ethical challenges. PLoS Med 2018;15:e1002689.
58. Ma H, Guo X, Ping Y, Wang B, Yang Y, Zhang Z, et al. PPCD: Privacy-preserving clinical decision with cloud support. PLoS One 2019;14:e0217349.
59. Dignum V. Ethics in artificial intelligence: introduction to the special issue. Ethics Inf Technol 2018;20:1–3.
60. Stupple A, Singerman D, Celi LA. The reproducibility crisis in the age of digital medicine. Npj Digital Medicine 2019;2:2.
61. Celi LA, Citi L, Ghassemi M, Pollard TJ. The PLOS ONE collection on machine learning in health and biomedicine: Towards open code and open data. PLoS One 2019;14:e0210232.
62. Lundberg SM, Nair B, Vavilala MS, Horibe M, Eisses MJ, Adams T, et al. Explainable machine-learning predictions for the prevention of hypoxaemia during surgery. Nature Biomedical Engineering 2018;2:749–60. doi:10.1038/s41551-018-0304-0.
63. Montavon G, Samek W, Müller K-R. Methods for interpreting and understanding deep neural networks. Digital Signal Processing 2018;73:1–15. doi:10.1016/j.dsp.2017.10.011.
64. Olah C, Mordvintsev A, Schubert L. Feature Visualization. Distill 2017;2. doi:10.23915/distill.00007.
65. Bau D, Zhou B, Khosla A, Oliva A, Torralba A. Network Dissection: Quantifying Interpretability of Deep Visual Representations. 2017 IEEE Conference on Computer Vision and Pattern Recognition (CVPR) 2017. doi:10.1109/cvpr.2017.354.
66. Yao Q, Wang M, Chen Y, Dai W, Yi-Qi H, Yu-Feng L, et al. Taking Human out of Learning Applications: A Survey on Automated Machine Learning 2018.
67. Olson RS, Moore JH. TPOT: A Tree-Based Pipeline Optimization Tool for Automating Machine Learning. Automated Machine Learning 2019:151–60. doi:10.1007/978-3-030-05318-5_8.
68. Jin H, Song Q, Hu X. Auto-Keras: An Efficient Neural Architecture Search System 2018.
69. Cloud AutoML - Custom Machine Learning Models | Google Cloud. Google Cloud n.d. https://cloud.google.com/automl/ (accessed July 28, 2019).
70. Szymkuć S, Gajewska EP, Klucznik T, Molga K, Dittwald P, Startek M, et al. Computer-Assisted Synthetic Planning: The End of the Beginning. Angew Chem Int Ed Engl 2016;55:5904–37.